Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3355 |
|
| Actual shortage: | 217 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-VALSARTAN/HCTZ | 12.5MG 160MG | TABLET | Resolved | 2017-03-10 | 2019-03-21 | 269 |
| APO-VALSARTAN/HCTZ | 25MG 160MG | TABLET | Resolved | 2017-03-11 | 2019-03-21 | 546 |
| APO-VALSARTAN/HCTZ | 12.5MG 320MG | TABLET | Resolved | 2017-03-11 | 2019-03-21 | 564 |
| APO-VALSARTAN/HCTZ | 25MG 320MG | TABLET | Resolved | 2017-03-11 | 2019-03-21 | 567 |
| APO-VARDENAFIL | 5MG | TABLET | Resolved | 2021-05-25 | 2021-11-01 | 139854 |
| APO-VARDENAFIL | 10MG | TABLET | Resolved | 2021-05-25 | 2021-11-02 | 139857 |
| APO-VARDENAFIL | 20MG | TABLET | Resolved | 2021-04-05 | 2021-10-25 | 136817 |
| APO-VARDENAFIL | 10MG | TABLET | Resolved | 2020-04-13 | 2020-05-11 | 111960 |
| APO-VARDENAFIL | 20MG | TABLET | Resolved | 2020-04-15 | 2020-05-11 | 112198 |
| APO-VARENICLINE | 0.5MG | TABLET | Resolved | 2019-10-30 | 2019-11-18 | 97477 |
| APO-VARENICLINE | 0.5MG | TABLET | Resolved | 2020-02-05 | 2020-03-27 | 105367 |
| APO-VARENICLINE | 1MG | TABLET | Resolved | 2020-04-13 | 2020-05-19 | 111957 |
| APO-VARENICLINE | 0.5MG 1MG | KIT TABLET | Resolved | 2020-04-13 | 2020-05-19 | 111963 |
| APO-VARENICLINE | 0.5MG | TABLET | Resolved | 2020-05-20 | 2020-06-15 | 115407 |
| APO-VARENICLINE | 0.5MG 1MG | KIT TABLET | Resolved | 2020-06-24 | 2020-08-10 | 118784 |
| APO-VARENICLINE | 1MG | TABLET | Resolved | 2020-07-23 | 2020-08-10 | 120988 |
| APO-VARENICLINE | 1MG | TABLET | Resolved | 2021-05-07 | 2025-01-31 | 138992 |
| APO-VARENICLINE | 0.5MG | TABLET | Resolved | 2021-07-05 | 2021-08-30 | 141857 |
| APO-VARENICLINE | 1MG 0.5MG | TABLET KIT | Resolved | 2021-11-29 | 2025-01-02 | 150175 |
| APO-VARENICLINE | 1MG | TABLET | Resolved | 2025-01-09 | 2025-04-04 | 247385 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |